GT 009
Alternative Names: GT-009Latest Information Update: 02 Feb 2024
At a glance
- Originator Glycotope
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 24 Jan 2024 GT 009 is available for licensing as of 24 Jan 2024. https://www.glycotope.com/partners/
- 24 Jan 2024 Early research in Cancer in Germany (Parenteral) (Glycotope pipeline, January 2024)